Newcastle University

Publications

Year: 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002 2001 2000 1999 1998 1997 1996 1995 1994 1993 1992 1991 1990 1989 1988 1987 1986 1984 1983 1980 1979

• Sinclair PB, Sorour A, Martineau M, Harrison CJ, Mitchell WA, O'Neill E, Foroni L. A fluorescence in situ hybridization map of 6q deletions in acute lymphocytic leukemia: identification and analysis of a candidate tumor suppressor gene. Cancer Research 2004, 64(12), 4089-4098.
• Willmore, E., De Caux, S., Sunter, N., Tilby, M.J., Jackson, G., Austin, C., Durkacz, B.W. A novel DNA-dependent protein kinase inhibitor, NU7026, potentiates the cytotoxicity of topoisomerase II poisons used in the treatment of leukemia. Blood 2004, 103(12), 4659-4665.
• Cooper, B., Veal, G.J., Radivoyevitch, T., Tilby, M., Meyerson, H., Lazarus, H., Koc, O., Creger, R., Pearson, G., Nowell, G., Gosky, D., Ingalls, S., Hoppel, C., Gerson, S. A phase I and pharmacodynamic study of fludarabine, carboplatin, and topotecan in patients with relapsed, refractory, or high-risk acute leukemia. Clinical Cancer Research 2004, 10(20), 6830-6839.
• Heer R, Dorkin TJ, Byrne RL, Griffiths TRL, Rangecroft L. A prospective audit of hypospadias correction in a regional paediatric surgery centre. European Journal of Pediatric Surgery 2004, 14(5), 328-332.
• Barber KE, Martineau M, Harewood L, Stewart M, Cameron E, Strefford JC, Rutherford S, Allen TD, Broadfield ZJ, Cheung KL, Harris RL, Jalali GR, Moorman AV, Robinson HM, Harrison CJ. Amplification of the ABL gene in T-cell acute lymphoblastic leukemia. Leukemia 2004, 18(6), 1153-1156.
• Zhu HN, Mazor M, Kawano Y, Walker MM, Leung HY, Armstrong K, Waxman J, Kypta RM. Analysis of Wnt gene expression in prostate cancer: Mutual enhibition by WNT11 and the androgen receptor. Cancer Research 2004, 64(21), 7918-7926.
• Calabrese C, Almassy R, Barton S, Batey M, Calvert AH, Canan-Koch S, Durkacz B, Hostomsky Z, Kumpf R, Kyle S, Li J, Maegley K, Newell DR, Notarianni E, Stratford I, Skalitzky D, Thomas HD, Wang L, Webber S, William K, Curtin NJ. Anticancer chemosensitization and radiosensitization by the novel poly(ADP-ribose) polymerase-1 inhibitor AG14361. Journal of the National Cancer Institute 2004, 96(1), 56-67.
• Sandy J, Holton S, Noble MEM, Sim E. Arylamine N-acetyltransferase from Mycobacterium smegmatis; An isoniazid metabolising enzyme in action. In: Drug Metabolism Reviews: 7th European ISSX Meeting. 2004, Vancouver, Canada: Taylor & Francis.
• Velangi MR, Matheson EC, Taylor PRA, Jackson GH, Hall AG, Irving JAE. BRAF gene is not mutated in mismatch repair-proficient or -deficient plasma cell dyscrasias . Leukemia 2004, 18(3), 658-659.
• Fisher L, Soomets U, Cortés ToroV, Chilton L, Jiang Y, Langel U, Iverfeldt K. Cellular delivery of a double-stranded oligonucleotide NFkappaB decoy by hybridization to complementary PNA linked to a cell-penetrating peptide. Gene Therapy 2004, 11(16), 1264-1272.
• Nicholson B, Gulding K, Conway M, Wedge SR, Theodorescu D. Combination antiangiogenic and androgen deprivation therapy for prostate cancer: a promising therapeutic approach. Clinical Cancer Research 2004, 10(24), 8728-8734.
• Lamont JM, McManamy CS, Pearson ADJ, Clifford SC, Ellison DW. Combined histopathological and molecular cytogenetic stratification of medulloblastoma patients. Clinical Cancer Research 2004, 10(16), 5482-5493.
• Gruszka-Westwood AM, Horsley SW, Martinez-Ramirez A, Harrison CJ, Kempski H, Moorman AV, Ross FM, Griffiths M, Greaves MF, Kearney L. Comparative expressed sequence hybridization studies of high-hyperdiploid childhood acute lymphoblastic leukemia. Genes, Chromosomes and Cancer 2004, 41(3), 191-202.
• Williamson D, Lu YJ, McIntyre A, Summersgill B, Wang RB, Selfe J, Cooper C, Clark J, Shipley J. Comparative genomic hybridisation and comparative expressed sequence hybridisation as complements to microarray analyses of tumours. Mutagenesis 2004, 19(6), 509-509.
• Logan, I. R., Sapountzi, V., Gaughan, L., Neal, D. E., Robson, C. N. Control of human PIRH2 protein stability: Involvement of TIP60 and the proteasome. Journal of Biological Chemistry 2004, 279(12), 11696-11704.
• Yule, S., Price, L., McMahon, A., Pearson, A. D. J., Boddy, A. V. Cyclophosphamide Metabolism in Children with Non-Hodgkin's Lymphoma. Clinical Cancer Research 2004, 10(2), 455-460.
• Goranov BB, Redfern CPF. Cytogenetic differences and neuroblastoma cell interconversion. Cancer Genetics and Cytogenetics 2004, 149(2), 173-174.
• Paleri V, Narayan R, Wight RG. Descriptive study of the type and severity of decompensation caused by comorbidity in a population of patients with laryngeal squamous cancer. Journal of Laryngology and Otology 2004, 118(7), 517-521.
• Tikhe J, Webber S, Hostomsky Z, Maegley K, Ekkers A, Li J, Yu X, Almassy R, Kumpf R, Boritzki T, Zhang C, Calabrese C, Curtin NJ, Kyle S, Thomas HD, Wang L, Calvert AH, Golding B, Griffin RJ, Newell DR. Design, synthesis, and evaluation of 3,4-dihydro-2H-[1,4]diazepino[6,7,1- hi]indol-1-ones as inhibitors of poly(ADP-ribose) polymerase. Journal of Medicinal Chemistry 2004, 47(22), 5467-5481.
• Pu M, May FEB, Playford R, Ruchaud-Sparagano M, Westley BR. Development of a two-site ELISA assay for the dimeric form of human TFF1. Peptides 2004, 25(5), 731-736.
• Potterton L, McNicholas S, Krissinel E, Gruber J, Cowtan K, Emsley P, Murshudov GN, Cohen S, Perrakis A, Noble M. Developments in the CCP4 molecular-graphics project. Acta Crystallographica Section D: Biological Crystallography 2004, 60(part 12), 2288-2294.
• Errington, F., Willmore, E., Leontiou, C., Tilby, M., Austin, C. Differences in the longevity of topo IIα and topo IIβ drug-stabilized cleavable complexes and the relationship to drug sensitivity. Cancer Chemotherapy and Pharmacology 2004, 53(2), 155-162.
• Velangi MR, Matheson EC, Morgan GJ, Jackson GH, Taylor PRA, Hall AG, Irving JAE. DNA mismatch repair pathway defects in the pathogenesis and evolution of myeloma. Carcinogenesis 2004, 25(10), 1795-1803.
• Humphray SJ, Oliver K, Hunt AR, Plumb RW, Loveland JE, Howe KL, Andrews TD, Searle S, Hunt SE, Scott CE, Jones MC, Ainscough R, Almeida JP, Ambrose KD, Ashwell RIS, Babbage AK, Babbage S, Bagguley CL, Bailey J, Banerjee R, Barker DJ, Barlow KF, Bates K, Beasley H, Beasley O, Bird CP, Bray-Allen S, Brown AJ, Brown JY, Burford D, Burrill W, Burton J, Carder C, Carter NP, Chapman JC, Chen Y, Clarke G, Clark SY, Clee CM, Clegg S, Collier RE, Corby N, Crosier M, Cummings AT, Davies J, Dhami P, Dunn M, Dutta I, Dyer LW, Earthrowl ME, Faulkner L, Fleming CJ, Frankish A, Frankland JA, French L, Fricker DG, Garner P, Garnett J, Ghori J, Gilbert JGR, Glison C, Grafham DV, Gribble S, Griffiths C, Jones SG, Grocock R, Guy J, Hall RE, Hammond S, Harley JL, Harrison ESI, Hart EA, Heath PD, Henderson CD, Hopkins BL, Howard PJ, Howden PJ, Huckle E, Johnson C, Johnson D, Joy AA, Kay M, Keenan S, Kershaw JK, Kimberley AM, King A, Knights A, Laird GK, Langford C, Lawlor S, Leongamornlert DA, Leversha M, Lloyd C, Lloyd DM, Lovell J, Martin S, Mashreghi-Mohammadi M, Matthews L, McLaren S, McLay KE, McMurray A, Milne S, Nickerson T, Nisbett J, Nordsiek G, Pearce AV, Peck AI, Porter KM, Pandian R, Pelan S, Phillimore B, Povey S, Ramsey Y, Rand V, Scharfe M, Sehra HK, Shownkeen R, Sims SK, Skuce CD, Smith M, Steward CA, Swarbreck D, Sycamore N, Tester J, Thorpe A, Tracey A, Tromans A, Thomas DW, Wall M, Wallis JM, West AP, Whitehead SL, Willey DL, Williams SA, Wilming L, Wray PW, Young L, Ashurst JL, Coulson A, Blocker H, Durbin R, Sulston JE, Hubbard T, Jackson MJ, Bentley DR, Beck S, Rogers J, Dunham I. DNA sequence and analysis of human chromosome 9. Nature 2004, 429(6990), 369-374.
• Veuger SJ, Curtin NJ, Smith G, Durkacz BW. Effects of novel inhibitors of poly(ADP-ribose) polymerase-1 and the DNA-dependent protein kinase on enzyme activities and DNA repair. Oncogene 2004, 23(44), 7322-7329.
• Veuger SJ, Curtin NJ, Smith GCM, Durkacz BW. Effects of novel inhibitors of poly(ADP-ribose) polymerase-1 and the DNA-dependent protein kinase on enzyme activities and DNA repair. Oncogene 2004, 23(44), 7322–7329.
• Cole M, Price L, Parry AP, Keir M, Pearson ADJ, Boddy A V, Veal GJ. Estimation of glomerular filtration rate in paediatric cancer patients using ⁵¹CR-EDTA population pharmacokinetics. British Journal of Cancer 2004, 90(1), 60-64.
• Davis AM, Gerrand C, Griffin A, O'Sullivan B, Hill RP, Wunder TS, Abudu A, Bell RS. Evaluation of clinical utility of BTC-2000 for measuring soft tissue fibrosis. International Journal of Radiation: Oncology - Biology - Physics 2004, 60(1), 286-294.
• May FEB, Semple J, Prest S, Westley BR. Expression and motogenic activity of TFF2 in human breast cancer cells. Peptides 2004, 25(5), 865-872.
• Paleri V, Pearson JP, Bulmer D, Jeannon JP, Wight RG, Wilson JA. Expression of much gene products in laryngeal squamous cancer. Otolaryngology - Head and Neck Surgery 2004, 131(1), 84-88.
• Heer, R,, Douglas, D. A., Robson, C. N., Leung, H. Y. Fibroblast growth factor (FGF) 17 expression is up-regulated human prostate cancer and correlates to clinical prognosis. British Journal of Cancer 2004, 91(Supplement 1), S20-S20.
• Heer, R., Douglas, D. A., Mathers, M. E., Robson, C. N., Leung, H. Y. Fibroblast growth factor 17 is over-expressed in human prostate cancer. Journal of Pathology 2004, 204(5), 578-586.
• Mehrotra, P., Okpokam, A., Bouhaidar, R., Johnson, S.J., Wilson, J., Davies, B.R., Lennard, T.W.J. Galectin-3 does not reliably distinguish benign from malignant thyroid neoplasms. Histopathology 2004, 45(5), 493-500.
• Lovat, P.E., Di Sano, F., Corazzari, M., Fazi, B., Donnorso, R., Pearson, A.D.J., Hall, A.G., Redfern, C.P.F., Piacentini, M. Gangliosides link the acidic sphingomyelinase-mediated induction of ceramide to 12-lipoxygenase-dependent apoptosis of neuroblastoma in response to fenretinide. Journal of the National Cancer Institute 2004, 96(17), 1288-1299.
• Nutt, J., Lazarowicz, H., Mellon, J., Lunec, J. Gefitinib ('Iressa', ZD1839) inhibits the growth response of bladder tumour cell lines to epidermal growth factor and induces TIMP2. British Journal of Cancer 2004, 90(8), 1679-1685.
• Horton R, Wilming L, Rand V, Lovering RC, Bruford EA, Khodiyar VK, Lush MJ, Povey S, Talbot Jr CC, Wright MW, Wain HM, Trowsdale J, Ziegler A, Beck S. Gene map of the extended human MHC. Nature Reviews Genetics 2004, 5(12), 889-899.
• Allan JM, Smith AG, Wheatly K, Hills RK, Travis LB, Hill DA, Swirsky DM, Morgan GJ, Wild CP. Genetic variation in XPD predicts treatment outcome and risk of acute myeloid leukemia following chemotherapy. Blood 2004, 104(13), 3872-3877.
• Liang, H., Atkins, H., Abdel-Fattah, R., Jones, S., Lunec, J. Genomic organisation of the human MDM2 oncogene and relationship to its alternatively spliced mRNAs. Gene 2004, 338(2), 217-223.
• Clyne M, Dillon P, Daly S, O'Kennedy R, May F, Westley B, Drumm B. Helicobacter pylori interacts with the human single-domain trefoil protein TFF1. Proceedings of the National Academy of Sciences of the United States of America 2004, 101(19), 7409-7414.
• Hickson, I., Zhao, Y., Richardson, C., Green, S., Martin, N., Orr, A., Reaper, P., Jackson, S., Curtin, N.J., Smith, G. Identification and characterization of a novel and specific inhibitor of the ataxia-telangiectasia mutated kinase ATM. Cancer Research 2004, 64(24), 9152-9159.
• Lindsey JC, Lusher ME, Anderton J, Bailey S, Gilbertson R, Pearson ADJ, Ellison DW, Clifford SC. Identification of tumour-specific epigenetic events in medulloblastoma development by hypermethylation profiling. Carcinogenesis 2004, 25(5), 661-668.
• Harris RL, Harrison CJ, Martineau M, Taylor KE, Moorman AV. Is trisomy 5 a distinct cytogenetic subgroup in acute lymphoblastic leukemia?. Cancer Genetics and Cytogenetics 2004, 148(2), 159-162.
• Heer R, Shrimankar J, Griffith CDM. Letter to the editor. Breast 2004, 13(3), 262.
• Syed, A.A., Irving, J.A.E., Redfern, C.P.F., Hall, A.G., Unwin, N.C., White, M., Bhopal, R., Alberti, K., Weaver, J.U. Low Prevalence of the N363S Polymorphism of the Glucocorticoid Receptor in South Asians Living in the United Kingdom. Journal of Clinical Endocrinology and Metabolism 2004, 89(1), 232-235.
• Barber KE, Ford AM, Harris RL, Harrison CJ, Moorman AV. MLL translocations with concurrent 3' deletions: interpretation of FISH results. Genes, Chromosomes and Cancer 2004, 41(3), 266-271.
• Lovat, P.E., Corazzari, M., Goranov, B., Piacentini, M., Redfern, C.P.F. Molecular mechanisms of fenretinide-induced apoptosis of neuroblastoma cells. Annals of the New York Academy of Sciences 2004, 1028, 81-89.
• Hardcastle IR, Arris CE, Bentley J, Boyle FT, Chen Y, Curtin NJ, Endicott JA, Gibson AE, Golding BT, Griffin RJ, Jewsbury, P., Menyerol, J., Mesguiche, V., Newell, D.R., Noble, M., Pratt, D., Wang, L., Whitfield, H.J. N2-substituted O6-cyclohexylmethylguanine derivatives: Potent inhibitors of cyclin-dependent kinases 1 and 2. Journal of Medicinal Chemistry 2004, 47(15), 3710-3722.
• Curtin NJ, Wang L, Yiakouvaki A, Kyle S, Arris C, Canan-Koch S, Webber S, Durkacz BW, Calvert AH, Hostomsky Z, Newell DR. Novel Poly(ADP-ribose) Polymerase-1 Inhibitor, AG14361, Restores Sensitivity to Temozolomide in Mismatch Repair-Deficient Cells. Clinical Cancer Research 2004, 10(3), 881-889.
• Veal, G. J., English, M., Grundy, R., Shakespeare, C., Glaser, A., Waters, F., Holden, V., O'Meara, A., Michalski, A., Howe, K., Cole, S., Boddy, A. V. Pharmacokinetically guided dosing of carboplatin in paediatric cancer patients with bilateral nephrectomy. Cancer Chemotherapy and Pharmacology 2004, 54(4), 295-300.
• White, A., Curtin, N.J., Eastman, B., Golding, B.T., Hostomsky, Z., Kyle,S., Li, J., Maegley, K., Skalitzky, D., Webber, S., Yu, X., Griffin, R.J. Potentiation of cytotoxic drug activity in human tumour cell lines, by amine-substituted 2-arylbenzimidazole-4-carboxamide PARP-1 inhibitors. Bioorganic and Medicinal Chemistry Letters 2004, 14(10), 2433-2437.
• Noble MEM, Endicott JA, Johnson LN. Protein kinase inhibitors: Insights into drug design from structure. Science 2004, 303(5665), 1800-1805.
• Curtin, N., Barlow, H., Bowman, K., Calvert, A. H., Davison, R., Golding, B., Huang, B., Loughlin, P., Newell, D., Smith, P., Griffin, R. Resistance-modifying agents. 11. Pyrimido[5,4-d]pyrimidine modulators of antitumor drug activity. Synthesis and structure-activity relationships for nucleoside transport inhibition and binding to α₁-acid glycoprotein. Journal of Medicinal Chemistry 2004, 47(20), 4905-4922.
• Heer, R., Collins, A. T., Robson, C. N., Leung, H. Y. Role of keratinocyte growth factor (KGF) and androgen in human prostatic epithelial stem cell differentiation. British Journal of Cancer 2004, 91(Supplement 1), S11-S11.
• Teriete P, Banerji S, Noble M, Blundell CD, Wright AJ, Pickford AR, Lowe E, Mahoney DJ, Tammi MI, Kahmann JD, Campbell ID, Day AJ, Jackson DG. Structure of the regulatory hyaluronan binding domain in the inflammatory leukocyte homing receptor CD44. Molecular Cell 2004, 13(4), 483-496.
• FitzGerald A, Pu M, Marchbank T, Westley BR, May FEB, Boyle J, Yadollahi-Farsani M, Ghosh S, Playford R. Synergistic effects of systemic trefoil factor family 1 (TFF1) peptide and epidermal growth factor in a rat model of colitis. Peptides 2004, 25(5), 793-801.
• Robinson HM, Taylor KE, Jalali GR, Cheung KL, Harrison CJ, Moorman AV. t(14;19)(q32;q13): a recurrent translocation in B-cell precursor acute lymphoblastic leukemia. Genes, Chromosomes and Cancer 2004, 39(1), 88-92.
• Newton J, Johns CE, May FEB. The ageing bowel and intolerance to aspirin. Alimentary Pharmacology and Therapeutics 2004, 19(1), 39-45.
• Newell DR, Silvester J, McDowell C, Burtles SS. The Cancer Research UK experience of pre-clinical toxicology studies to support early clinical trials with novel cancer therapies. European Journal of Cancer 2004, 40(6), 899-906.
• Coulthard SA, Matheson EC, Hall AG, Hogarth LA. The clinical impact of thiopurine methyltransferase polymorphisms on thiopurine treatment. In: Joint 11th International and 9th European Symposium on Purines and Pyrimidines. 2004, Man Egmond Aan Zee, Netherlands: Nucleosides, Nucleotides and Nucleic Acids: Taylor & Francis Inc.
• Ellison D, Lamont I, McManamy C, Pearson A, Clifford S. The clinical utility of stratifying medulloblastomas (MBs) by a combination of detailed histopathologic evaluation and molecular cytogenetic analysis. In: 80th Annual Meeting of the American Association of Neuropathologists. 2004, Cleveland, Ohio: Journal of Neuropathology and Experimental Neurology: American Assocation of Neuropathologists.
• Smith V, Steen IN, Dear A, Kelly CG, Welch AR, Meikle D, Stafford FW, Wilson JA. The effect of treatment modality on Quality of Life after Laryngeal Cancer. J Laryngol Otol 2004, 118, 232-38.
• Gerrand CH, Wunder JS, Kandel RA, O'Sullivan B, Catton CN, Bell RS, Griffin AM, Davis AM. The influence of anatomic location on functional outcome in lower-extremity soft-tissue sarcoma. Annals of Surgical Oncology 2004, 11(5), 476-482.
• Martinez N, Drescher B, Riehle H, Cullmann C, Vornlocher HP, Ganser A, Heil G, Nordheim A, Krauter J, Heidenreich O. The oncogenic fusion protein RUNX1-CBFA2T1 supports proliferation and inhibits senescence in t(8;21)-positive leukaemic cells. BMC Cancer 2004, 4(1), 44.
• Chilton L, Middlemas A, Gardiner N, Tomlinson DR. The p75 neurotrophin receptor appears in plasma in diabetic rats-characterisation of a potential early test for neuropathy. Diabetologia 2004, 47(11), 1924-1930.
• Aspinall, S., Stamp, S., Davison, A., Shenton, B.K., Lennard, T.W.J. The proliferative effects of 5-androstene-3β,17β-diol and 5α-dihydrotestosterone on cell cycle analysis and cell proliferation in MCF7, T47D and MDAMB231 breast cancer cell lines. Journal of Steroid Biochemistry and Molecular Biology 2004, 88(1), 37-51.
• Pratt DJ, Endicott JA, Noble MEM. The role of structure in kinase-targeted inhibitor design. Current Opinion In Drug Discovery & Development 2004, 7(4), 428-436.
• Frank AJ, Hernan R, Hollander A, Lindsey JC, Lusher ME, Fuller CE, Clifford SC, Gilbertson RJ. The TP53-ARF tumor suppressor pathway is frequently disrupted in large/cell anaplastic medulloblastoma. Molecular Brain Research 2004, 121(1-2), 137-140.
• Ruchaud-Sparagano M, Westley BR, May FEB. The trefoil protein TFF1 is bound to MUC5AC in human gastric mucosa. Cellular and Molecular Life Sciences 2004, 61(15), 1946-1954.
• Drevs J, Konerding MA, Wolloscheck T, Wedge SR, Ryan AJ, Ogilvie DJ, Esser N. The VEGF receptor tyrosine kinase inhibitor, ZD6474, inhibits angiogenesis and affects microvascular architecture within an orthotopically implanted renal cell carcinoma. Angiogenesis 2004, 7(4), 347-354.
• Harrison CJ, Moorman AV, Broadfield ZJ, Cheung KL, Harris RL, Jalali GR, Robinson HM, Barber KE, Richards SM, Mitchell CD, Eden TO, Hann IM, Hill FG, Kinsey SE, Gibson BES, Lilleyman J, Vora A, Goldstone AH, Franklin IM, Durrant J, Martineau M. Three distinct subgroups of hypodiploidy in acute lymphoblastic leukaemia. British Journal of Haematology 2004, 125(5), 552-559.
• Carrasco R, Pera M, May F, Westley B, Martinez A, Morales L. Trefoil factor family peptide 3 prevents the development and promotes healing of ischemia-reperfusion injury in weanling rats. Journal of Pediatric Surgery 2004, 39(11), 1693-1700.
• Soriano-Izquierdo A, Gironella M, Massaguer A, May FEB, Salas A, Sans M, Poulsom R, Thim L, Piqué J, Panés J. Trefoil peptide TFF2 treatment reduces VCAM-1 expression and leukocyte recruitment in experimental intestinal inflammation. Journal of Leukocyte Biology 2004, 75(2), 214-223.
• Heer R, Shrimankar J, Griffith CDM. Untitled - Letter. The Breast 2004, 13(3), 262-262.
• Halkidou, K., Gaughan, L., Cook, S., Leung, H. Y., Neal, D. E., Robson, C. N. Upregulation and nuclear recruitment of HDACI in hormone refractory prostate cancer. The Prostate 2004, 59(2), 177-189.
• Irving JAE, O'Brien S, Lennard A, Minto CLJ, Lin F, Hall AG. Use of Denaturing HPLC for Detection of Mutations in the BCR-ABL Kinase Domain in Patients Resistant to Imatinib. Clinical Chemistry 2004, 50(7), 1233-1237.
• Williams KJ, Telfer BA, Brave S, Kendrew J, Whittaker L, Stratford IJ, Wedge SR. ZD6474, a potent inhibitor of vascular endothelial growth factor signaling, combined with radiotherapy: schedule-dependent enhancement of antitumor activity. Clinical Cancer Research 2004, 10(24), 8587-8593.